drugset / Trial / NCT07124221
A Phase III Clinical Study of Cabergoline Tablets Compared With Bromocriptine Mesylate Tablets
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A Phase III clinical study evaluating the efficacy and safety of cabergoline tablets versus bromocriptine mesylate tablets in patients with hyperprolactinemia
Timeline
- Start
- 2025-09-12
- Primary completion
- 2026-11-21
- Completion
- 2026-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bromocriptine | Small molecule | 1.25 mg | — |
| Comparator | Bromocriptine | Small molecule | 7.5 mg | — |
| Subject | Cabergoline | Small molecule | 0.25 mg | — |
| Subject | Cabergoline | Small molecule | 1 mg | — |